Search Results
6 results found-
ToVs solely related to over-the-counter medicines - ToVs excluded from the scope of the EFPIA Disclosure Code, such as informational and educational materials, items of medical utility, food and beverage, medical samples - Fees charged by logistics agencies assisting in organising travel and meetings -
https://www.csl.com/-/media/shared/documents/vifor-disclosures/methodological-notes/methodological-note_2022_ch.pdf -
ToVs solely related to over-the-counter medicines - ToVs excluded from the scope of the EFPIA Disclosure Code, such as informational and educational materials, items of medical utility, food and beverage, medical samples - Fees charged by logistics agencies assisting in organising travel and meetings -
https://www.csl.com/-/media/shared/documents/vifor-disclosures/methodological-notes/methodological-note-romania-2021.pdf -
This means information that a reasonable person would expect to have a material effect on the price or value of CSL's securities, being any information that would, or would be likely to, influence persons who commonly invest in securities in deciding whether or not to subscribe for, buy or sell those securities.
https://www.csl.com/-/media/shared/documents/one-csl/csl-governance-docs/continuous-disclosure-policy.pdf -
ToVs solely related to over-the-counter medicines - ToVs excluded from the scope of the EFPIA Disclosure Code, such as informational and educational materials, items of medical utility, food and beverage, medical samples - Fees charged by logistics agencies assisting in organising travel and meetings -
https://www.csl.com/-/media/shared/documents/vifor-disclosures/methodological-notes/methodological-note-ireland-2021.pdf -
ToVs solely related to over-the-counter medicines - ToVs excluded from the scope of the EFPIA Disclosure Code, such as informational and educational materials, items of medical utility, food and beverage, medical samples - Fees charged by logistics agencies assisting in organising travel and meetings -
https://www.csl.com/-/media/shared/documents/vifor-disclosures/methodological-notes/methodological-note-switzerland-2021.pdf -
It is a global, randomized, multicenter, double-blind, parallel-arm, active-controlled clinical trial evaluating the safety and efficacy of 400 mg of sparsentan, compared to 300 mg of irbesartan, in 404 patients ages 18 years and up with IgAN and persistent proteinuria despite receiving maximum tolerated dose and at least 50% of maximum labelled dose of ACE or ARB therapy.
https://newsroom.csl.com/2024-02-23-CSL-Vifor-and-Travere-Therapeutics-announce-sparsentan-receives-positive-CHMP-opinion-for-the-treatment-of-IgA-nephropathy